PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Cancer statistics PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Reimbursement and coverage: An overview • Current scenario: Validating diagnostic tests • Reimbursement structure in US • Reimbursement structure in EU PART 08: Cancer diagnostic devices: Pricing scenario PART 09: Market segmentation by product • Global companion cancer diagnostic devices market • Global molecular cancer diagnostic devices market PART 10: Market segmentation by cancer type • Lung cancer • Breast cancer • Colorectal cancer • Prostate cancer • Cervical cancer PART 11: Geographical segmentation • Cancer diagnostic devices market in Americas • Cancer diagnostic devices market in EMEA • Cancer diagnostic devices market in APAC PART 12: Market drivers • Prevalence of cancer • Need for cost-cutting in drug discovery and development • Demand for personalized medicines • Advances in technology • Focus on emerging countries PART 13: Impact of drivers PART 14: Market challenges • Unfavorable reimbursement scenario • High cost of developing companion diagnostics • Stringent regulatory framework • Lack of skilled personnel PART 15: Impact of drivers and challenges PART 16: Market trends • Adoption of various strategies • Increase in R&D • Product approvals and launches PART 17: Vendor landscape • Competitive scenario • Keys news • M&A PART 18: Key vendors • Abbott Diagnostics • Agilent Technologies • BD • bioMérieux • Qiagen • Roche Diagnostics • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio Exhibit 01: Product offerings Exhibit 02: Prevalent cancer types worldwide 2012 Exhibit 03: Top countries with highest cancer rate worldwide 2012 Exhibit 04: Cancer statistics by gender 2012 Exhibit 05: Global cancer diagnostic devices market 2015-2020 ($ billions) Exhibit 06: Five forces analysis Exhibit 07: Reimbursement perspectives of healthcare entities Exhibit 08: Factors influencing cost of cancer diagnostic devices Exhibit 09: Global cancer diagnostic devices market segmentation by product Exhibit 10: Global companion cancer diagnostic devices market 2015-2020 ($ millions) Exhibit 11: Global molecular cancer diagnostic devices market 2015-2020 ($ billions) Exhibit 12: Global cancer diagnostic devices market segmentation by cancer type 2015 Exhibit 13: Cancer types and associated diagnosis methods Exhibit 14: Global cancer diagnostic devices market segmentation by geography 2015 Exhibit 15: Global cancer diagnostic devices market segmentation by geography 2020 Exhibit 16: Global cancer diagnostic devices market segmentation by geography 2015-2020 ($ millions) Exhibit 17: Global cancer diagnostic devices market segmentation by geography 2015-2020 Exhibit 18: Cancer diagnostic devices market in Americas 2015-2020 ($ billions) Exhibit 19: Cancer diagnostic devices market in EMEA 2015-2020 ($ millions) Exhibit 20: Cancer diagnostic devices market in APAC 2015-2020 ($ millions) Exhibit 21: Impact of drivers Exhibit 22: Impact of drivers and challenges Exhibit 23: Abbott Diagnostics: Product portfolio Exhibit 24: Abbott Diagnostics: Key takeaways Exhibit 25: Agilent Technologies: Product portfolio Exhibit 26: Agilent Technologies: Revenue of diagnostics and genomics segment 2013-2015 ($ millions) Exhibit 27: Agilent Technologies: Key takeaways Exhibit 28: BD: Product portfolio Exhibit 29: BD: Revenue of life sciences segment 2013-2015 ($ billions) Exhibit 30: BD: Key takeaways Exhibit 31: bioMérieux: Product portfolio Exhibit 32: bioMérieux: Key takeaways Exhibit 33: Qiagen: Product portfolio Exhibit 34: Qiagen: Revenue of consumable and related products 2013-2015 ($ billions) Exhibit 35: Qiagen: Key takeaways Exhibit 36: Roche Diagnostics: Product portfolio Exhibit 37: Roche Diagnostics: Revenue of molecular diagnostics segment 2013-2015 ($ billions) Exhibit 38: Roche Diagnostics: Key takeaways Exhibit 39: Other prominent vendors

Abbott Diagnostics, Agilent Technologies, BD, bioMérieux, Qiagen, Roche Diagnostics, Affymetrix, Ambry Genetics, Annoroad, Aviva Biosciences, Biochain, Bio-Rad, Cancer Genetics, Cepheid, CompanionDx, DiagnoCure, Epic Sciences, Epigenomics, Genomic Health, HalioDX, Hologic, Illumina, Myriad Genetics, Thermo Fisher Scientific, Ventana Medical Systems, Vysis.